Current Challenges in Management of Neurological Disorders (Part-I)

Mohammad    Amjad    Kamal; Mohamed    M.    Abdel-Daim

doi:10.2174/138161282607200309122739

[1] 
Bakir S, Catalkaya G, Ceylan FD, et al. Role of dietary antioxidants in neurodegenerative diseases: where are we standing? Curr Pharm Des  2020; 26(7): 714-29.
[2] 
Gulla S, Lomada D, Anusha L, Reddanna P, Reddy MC. Role of prostaglandins in multiple sclerosis. Curr Pharm Des  2020; 26(7): 730-42.
[3] 
Nadeema MS, Al-Abbasia FA, Zamzamia MA, et al. Multiple risk factors: a challenge in the management of Autism. Curr Pharm Des  2020; 26(7): 743-54.
[4] 
Singh K, Yadav D, Chouhan P, Mishra M, Jin JO. Novel therapeutics for the treatment of Alzheimer’s and Parkinson’s disorders. Curr Pharm Des  2020; 26(7): 755-63.
[5] 
Tran PHL, Duan W, Lee B-J, Tran TTD. Current perspectives on delivery systems using extracellular vesicles in neurological disease. Curr Pharm Des  2020; 26(7): 764-71.
[6] 
Rahman MA, Rahman MR, Zaman T, et al. The emerging potential of naturally occurring autophagy modulators against neurodegeneration. Curr Pharm Des  2020; 26(7): 772-9.
[7] 
Wang L, Liu S, Xu J, et al. A traditional Chinese medicine, YXQN, reduces amyloid-induced cytotoxicity by inhibiting Aβ42 aggregation and fibril formation. Curr Pharm Des  2020; 26(7): 780-9.
[8] 
Jamal QMS, Siddiqui MU, Alharbi AH, et al. A computational study of natural compounds from Bacopa monnieri in the treatment of Alzheimer’s disease. Curr Pharm Des  2020; 26(7): 790-800.

Rights & Permissions Print Cite

Article Metrics

5

2

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/138161282607200309122739	Print ISSN 1381-6128
Publisher Name Bentham Science Publisher	Online ISSN 1873-4286

Current Pharmaceutical Design

Current Challenges in Management of Neurological Disorders (Part-I)

Related Journals

Related Books